

A full list of Jazz Pharmaceuticals' presentations follows below:

Presentation Title	Lead Author	Poster Number / Session Title / Date & Time (PT)
Xywav Data		
Self-Reported Cognitive Complaints and Work Productivity in Participants With Narcolepsy After Low-Sodium Oxybate treatment: Results From the Phase 4 DUET Study	LD Schneider	Poster #: 002 Session: P8 Sleep 2 Session Date/Time: Tuesday, April 8, 8:00 AM – 9:00 AM
Effectiveness and Safety of Low-Sodium Oxybate in Participants With Narcolepsy: Top-line Results From the Phase 4 DUET Study	LD Schneider	Poster #: 008 Session: P10: General Neurology: New, Potential, and Innovative Treatments 2 Session Date/Time: Tuesday, April 8, 5:00 PM – 6:00 PM
Efficacy and Safety of Low-Sodium Oxybate in Narcolepsy Patients With/Without Psychiatric/Neurologic Comorbidities	C Chepke	Poster #: 004 Session: P12 General Neurology Posters 5 Session Date/Time: Wednesday, April 9, 11:45 AM – 12:45 PM
Epidiolex Data		
Dosing Patterns and Persistence on Cannabidiol (CBD) – Insights From US Specialty Pharmacy Data	G Pohl	Poster #: 005 Session: P12: Epilepsy/Clinical Neurophysiology (EEG): Retrospective Studies, Reviews, and Meta-analyses in Epilepsy Session Date/Time: Wednesday, April 9, 11:45 AM – 12:45 PM
Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorder (TAND) Outcomes Following Add-on Cannabidiol (CBD) Treatment: 3-Month Analysis of Open-Label Phase 3b/4 Trial EpiCom	A van Eeghen	Poster #: 005 Session: P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials Session Date/Time: Tuesday, April 8, 8:00 AM – 9:00 AM
Caregiver-Reported Real-World Use of Cannabidiol (CBD) and Effects on Seizures and Caregiver Burden: Results From the CARE-EpiC Survey	S Thomas	Poster #: 003 Session: P1: Epilepsy/Clinical Neurophysiology (EEG): Special Populations: Women with Epilepsy, Caregivers, Adolescents, and Elderly Session Date/Time: Saturday, April 5, 11:45 AM – 12:45 PM

Nurse-Reported Outcomes of Cannabidiol (CBD) Treatment in the Long-Term Care (LTC) Setting: Results From the BECOME-LTC Survey	N Wrobel	Poster #: 016 Session: P2: Epilepsy/Clinical Neurophysiology (EEG): Clinical Outcomes in Epilepsy Session Date/Time: Sunday, April 6, 8:00 AM – 9:00 AM PT
--	----------	--

The DEA defines Schedule III drugs, substances, or chemicals as drugs with a moderate to low potential for physical and psychological dependence.^{1,2} Because of the risks of central nervous system (CNS) depression and abuse and misuse, *Xywav* is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS.